Ono Pharmaceutical Co Ltd (OPHLY)
Ono Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company whose ordinary shares are represented in the U.S. through an ADR listed on OTC Markets. The company develops, manufactures, purchases, and sells pharmaceuticals and diagnostic reagents in global markets. Its portfolio includes treatments for oncology, immunology, neurology, cardiovascular and metabolic conditions, and other therapeutic areas. Products named in the source include Opdivo, Kyprolis, Emend, Mektovi, Velexbru, Braftovi, ADLUMIZ, Glactiv, Forxiga, Onoact, Opalmon, Coralan, Orencia, Rivastach, Ongentys, Parsabiv, Staybla, Onon, Dry Syrups, Joyclu, and Recalbon. Ono also continues to develop therapies across multiple disease categories and works with partners including Adimab LLC, Turbine Ltd., Harvard University, Sibylla Biotech, and Congruence Therapeutics. The company was founded in 1717 and is headquartered in Osaka, Japan.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-OPHL.Y
|
$5.62
|
15.5% Upside
|
Fair
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
0.0%
|
July 31, 2026
|
16.3x
|
1.3x
|
2.2x
|
6.924 B
|
5.826 B
|
9.5%
|
96.5%
|
14.2
|
53.8%
|
187.5%
|
